keyword
MENU ▼
Read by QxMD icon Read
search

Gastroesophagic junction cancer

keyword
https://www.readbyqxmd.com/read/28524708/significance-of-baseline-fdg-pet-ct-scan-as-a-method-of-staging-regional-lymph-nodes-in-patients-with-operable-distal-oesophageal-or-gastroesophageal-junction-adenocarcinoma
#1
George Papaxoinis, Jamie M J Weaver, Leila Khoja, Ana Patrao, Sofia Stamatopoulou, Alia Alchawaf, Vikki Owen-Holt, Theodora Germetaki, Zoe Kordatou, Wasat Mansoor
BACKGROUND: The new American Joint Committee on Cancer eighth edition (AJCC8) staging is the first to describe separate clinical and pathology staging systems, but still has low performance to predict prognosis in patients with oesophageal/gastroesophageal junction (O/GOJ) adenocarcinoma, who are candidates for surgery. Recent studies have demonstrated that O/GOJ cancer patients with 18F-fluorodeoxyglucose (FDG) avid regional lymph nodes (RLNs) may have poor prognosis. The aim of our study was to examine whether the baseline assessment of the FDG uptake of RLN improves the prognostic accuracy of the new AJCC8 staging...
May 19, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/28501091/update-on-gastroesophageal-adenocarcinoma-targeted-therapies
#2
REVIEW
Steven B Maron, Daniel V T Catenacci
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) incidence is rising. GC and EGJ, together, are treated uniformly in the metastatic setting as GEC. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to date-only first-line anti-HER2 therapy for ERBB2 amplification and second-line anti-VEGFR2 therapy...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28501090/antiangiogenic-therapy-in-gastroesophageal-cancer
#3
REVIEW
Zhaohui Jin, Harry H Yoon
Antiangiogenesis therapy is one of only 2 biologically targeted approaches shown to improve overall survival over standard of care in advanced adenocarcinoma of the stomach or gastroesophageal junction (GEJ). Therapeutic targeting of vascular endothelial growth factor receptor 2 improves overall survival in patients with previously treated advanced gastric/GEJ adenocarcinoma. No antiangiogenesis therapy has demonstrated an overall survival benefit in patients with chemo-naïve or resectable esophagogastric cancer or in patients whose tumors arise from the esophagus...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28501087/the-role-of-radiotherapy-in-localized-esophageal-and-gastric-cancer
#4
REVIEW
John Ng, Percy Lee
Multimodality management has become a core treatment principle for locally advanced esophageal, gastroesophageal junction (GEJ), and gastric cancer. Radiotherapy serves an important role for optimizing patient outcomes. This article reviews the evolving role of radiotherapy in the multidisciplinary management of esophageal, GEJ, and gastric cancer, summarizing the results of recent clinical trials leading to contemporary accepted treatment approaches. A major theme is the evidence supporting the role of radiotherapy in combined modality management, particularly the trend toward its delivery in the neoadjuvant setting...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28501086/management-of-locally-advanced-gastroesophageal-cancer-still-a-multidisciplinary-global-challenge
#5
REVIEW
Salah-Eddin Al-Batran, Sylvie Lorenzen
The outcome of patients with locally advanced, resectable gastric cancer, or adenocarcinoma of the gastroesophageal junction is poor. In clinical trials, multimodality therapy, such as perioperative chemotherapy, preoperative or postoperative chemoradiation, or adjuvant chemotherapy led to significant increments in survival. Therefore, experts agree that patients with stage II or III disease should be offered a multidisciplinary treatment approach. However, patients are treated somewhat differently in the different regions of the world and survival rates remain far from being satisfactory...
June 2017: Hematology/oncology Clinics of North America
https://www.readbyqxmd.com/read/28500616/significance-of-blood-neutrophil-to-lymphocyte-ratio-for-prognostic-stratification-of-patients-with-gastroesophageal-junction-adenocarcinoma-in-the-era-of-the-8th-edition-of-the-american-joint-committee-on-cancer-ajcc8-staging
#6
Alicia-Marie Conway, Zena Salih, George Papaxoinis, Kimberly Fletcher, Jamie Weaver, Ana Patrao, Robert Noble, Sofia Stamatopoulou, Vikki Owen-Holt, Wasat Mansoor
The prognosis of patients with gastroesophageal junction (GOJ) adenocarcinoma depends mainly on the clinical staging, as described by the new AJCC8 (American Joint Committee on Cancer 8th edition). Evidence suggests that peripheral blood neutrophil-to-lymphocyte ratio (NLR) may be of prognostic significance in patients with upper gastrointestinal cancers. We examined the prognostic significance of NLR in the era of the new AJCC8 staging system. In this single-centre cohort study, retrospective data on patients with operable GOJ adenocarcinoma treated with perioperative chemotherapy were analysed...
June 2017: Medical Oncology
https://www.readbyqxmd.com/read/28475728/a-retrospective-comparison-of-neoadjuvant-chemoradiotherapy-regimens-for-locally-advanced-esophageal-cancer
#7
N N Sanford, P J Catalano, P C Enzinger, B L King, R Bueno, N E Martin, T S Hong, J Y Wo, H J Mamon
Preoperative chemoradiotherapy (CRT) with carboplatin/paclitaxel has been shown to increase survival in patients with esophageal cancer, including gastroesophageal junction (GE) junction cancer, over surgery alone; however, there have been no studies comparing the different neoadjuvant CRT regimens. We retrospectively evaluated the long-term results of trimodality therapy for patients with locally advanced esophageal cancer treated on several chemotherapy regimens. Between 1999 and 2014, 215 patients with locally advanced esophageal cancer underwent neoadjuvant CRT followed by surgical resection...
July 1, 2017: Diseases of the Esophagus: Official Journal of the International Society for Diseases of the Esophagus
https://www.readbyqxmd.com/read/28448662/effect-of-neoadjuvant-chemotherapy-followed-by-surgical-resection-on-survival-in-patients-with-limited-metastatic-gastric-or-gastroesophageal-junction-cancer-the-aio-flot3-trial
#8
Salah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, Gerald Illerhaus, Uwe M Martens, Jan Stoehlmacher, Harald Schmalenberg, Kim B Luley, Nicole Prasnikar, Matthias Egger, Stephan Probst, Helmut Messmann, Markus Moehler, Wolfgang Fischbach, Jörg T Hartmann, Frank Mayer, Heinz-Gert Höffkes, Michael Koenigsmann, Dirk Arnold, Thomas W Kraus, Kersten Grimm, Stefan Berkhoff, Stefan Post, Elke Jäger, Wolf Bechstein, Ulrich Ronellenfitsch, Stefan Mönig, Ralf D Hofheinz
Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective: To evaluate outcome in patients with limited metastatic disease who receive chemotherapy first and proceed to surgical resection. Design, Setting, and Participants: The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma...
April 27, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28425657/different-time-trend-and-management-of-esophagogastric-junction-adenocarcinoma-in-three-asian-countries
#9
Waku Hatta, Daniel Tong, Yeong Yeh Lee, Shin Ichihara, Noriya Uedo, Takuji Gotoda
Esophagogastric junction (EGJ) adenocarcinoma has been on the increase in Western countries. However, in Asian countries, data on the incidence of EGJ adenocarcinoma are evidently lacking. In the present review, we focus on the current clinical situation of EGJ adenocarcinoma in three Asian countries: Japan, Hong Kong, and Malaysia. The incidence of EGJ adenocarcinoma has been reported to be gradually increasing in Malaysia and Japan, whereas it has stabilized in Hong Kong. However, the number of cases in these countries is comparatively low compared with Western countries...
April 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/28425653/endoscopic-gastric-mucosal-atrophy-distinguishes-the-characteristics-of-superficial-esophagogastric-junction-adenocarcinoma
#10
Noriya Uedo, Toshiyuki Yoshio, Shigetaka Yoshinaga, Manabu Takeuchi, Waku Hatta, Tomonori Yano, Tokuma Tanuma, Osamu Goto, Akiko Takahashi, Daniel Tong, Yeong Yeh Lee, Yoshiko Nakayama, Shin Ichihara, Takuji Gotoda
BACKGROUND AND AIM: Western studies have suggested two distinct etiologies of esophagogastric junction (EGJ) cancer: Helicobacter pylori-associated atrophic gastritis and non-atrophic gastric mucosa resembling esophageal adenocarcinoma. The present study investigated whether endoscopic gastric mucosal atrophy can distinguish between these two types of EGJ adenocarcinoma. METHODS: Data were collected from patients with Siewert type II, T1 EGJ adenocarcinoma who underwent endoscopic or surgical resection at eight Japanese institutions in 2010-2015...
April 2017: Digestive Endoscopy: Official Journal of the Japan Gastroenterological Endoscopy Society
https://www.readbyqxmd.com/read/28416743/the-urokinase-plasminogen-activation-system-in-gastroesophageal-cancer-a-systematic-review-and-meta-analysis
#11
Daniel Brungs, Julia Chen, Morteza Aghmesheh, Kara L Vine, Therese M Becker, Martin G Carolan, Marie Ranson
BACKGROUND: The urokinase plasminogen activation (uPA) system is a crucial pathway for tumour invasion and establishment of metastasis. Although there is good evidence that uPA system expression is a clinically relevant biomarker in some solid tumours, its role in gastroesophageal cancer is uncertain. RESULTS: We identified 22 studies encompassing 1966 patients which fulfilled the inclusion criteria. uPA, uPAR, or PAI-1 expression is significantly associated with high risk clinicopathological features...
April 4, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415835/the-role-of-chemotherapy-in-unresectable-or-metastatic-adenocarcinoma-of-the-stomach-and-gastroesophageal-junction
#12
Mustafa Bozkurt, Fatemeh G Amlashi, Mariela Blum Murphy
Gastric cancer including gastro-esophageal junction adenocarcinomas are most challenging and deadly cancers of the gastrointestinal tract. Gastric cancer has a fatality-to-case ratio of 0.66, translating that nearly two thirds of newly diagnosed patients will have disseminated disease and in need of systemic therapy (1). Advanced gastric adenocarcinoma (AGC) is a heterogenous disease with differences in geographical distribution, histopathology, and molecular subtypes. Fluoropyrimidines (5-FU, S-1, and capecitabine), platinum compounds (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and the topoisomerase inhibitory irinotecan are active drugs against AGC...
April 14, 2017: Minerva Chirurgica
https://www.readbyqxmd.com/read/28386965/perioperative-chemotherapy-versus-postoperative-chemoradiotherapy-in-patients-with-resectable-gastric-gastroesophageal-junction-adenocarcinomas-a-survival-analysis-of-5058-patients
#13
Timothy L Fitzgerald, Jimmy T Efird, Nelly Bellamy, Suzanne M Russo, Charulata Jindal, Catalina Mosquera, Elizabeth G Holliday, Tithi Biswas
BACKGROUND: Both perioperative chemotherapy (PECT) and postoperative chemoradiotherapy (POCRT) have a significant survival advantage over surgery alone for the treatment of patients with gastric cancer. However, to the best of our knowledge, these regimens have not been compared in a randomized clinical trial. The purpose of the current observational study was to compare overall survival among patients receiving PECT versus POCRT for the treatment of gastric/gastroesophageal junction (GEJ) adenocarcinomas...
April 6, 2017: Cancer
https://www.readbyqxmd.com/read/28384630/esophageal-cancer-new-insights-into-a-heterogenous-disease
#14
Sebastian Krug, Patrick Michl
BACKGROUND: Esophageal cancer represents a heterogeneous malignancy mostly diagnosed in advanced stages. Worldwide, squamous cell carcinomas (SCCs) continue to be the most prevalent subtype; however, in the Western countries, the incidence of adenocarcinomas is increasing and will exceed that of SCC in the near future. During the last decade, several landmark trials contributed to a better understanding of the disease and emphasized the importance of multimodal treatment protocols. SUMMARY: With the introduction of perioperative or neoadjuvant approaches, the survival of both subtypes of esophageal cancer has significantly improved...
April 7, 2017: Digestion
https://www.readbyqxmd.com/read/28349718/overview-of-different-available-chemotherapy-regimens-combined-with-radiotherapy-for-the-neoadjuvant-and-definitive-treatment-of-esophageal-cancer
#15
Gianluca Tomasello, Michele Ghidini, Sandro Barni, Rodolfo Passalacqua, Fausto Petrelli
Neoadjuvant chemoradiotherapy (CTRT) is the current standard of care for treatment of locally advanced cancer of the esophagus or gastroesophageal junction. Many efforts have been made over the last years to identify the best chemotherapy and radiotherapy combination regimen, but specific randomized trials addressing this issue are still lacking. Areas covered: A systematic review of the literature was performed searching in PubMed all published studies of combinations CTRT regimens for operable or unresectable esophageal cancer to describe activity and toxicity...
June 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28337865/helicobacter-pylori-and-barrett%C3%A2-s-esophagus-a-protective-factor-or-a-real-cause
#16
G Tomasello, F Giordano, M Mazzola, R Jurjus, A Jurjus, P Damiani, S Nobile, F Carini, A Leone
Notwithstanding the definite aetiopathogenetic path of certain diseases, the relationship between Helicobacter pylori (H. pylori) and Barrett’s esophagus (BE), a condition that increases the risk for dysplasia and consequently adenocarcinoma of the distal esophagus and esophagogastric junction, remains uncertain. This paper reviews the current scientific literature with emphasis on the protective correlation between H. pylori infection and BE and demonstrates that a causal relationship has not been disproved with certainty...
January 2017: Journal of Biological Regulators and Homeostatic Agents
https://www.readbyqxmd.com/read/28337363/epidemiologic-study-of-human-epidermal-growth-factor-receptor-2-expression-in-advanced-metastatic-gastric-cancer-an-assessment-of-human-epidermal-growth-factor-receptor-2-status-in-tumor-tissue-samples-of-gastric-and-gastro-esophageal-junction-cancer
#17
Kyung Won Seo, Taeyong Jeon, Sewon Kim, Sung Soo Kim, Kwanghee Kim, Byoung-Jo Suh, Sunhwi Hwang, SeongHee Choi, Seungwan Ryu, Jae Seok Min, Young-Joon Lee, Ye Seob Jee, Hyeondong Chae, Doo Hyun Yang, Sang Ho Lee
PURPOSE: The Trastuzumab for gastric cancer (GC) trial identified human epidermal growth factor receptor 2 (HER2) as a predictor of successful treatment with trastuzumab (HER2 receptor targeting agent) among patients with advanced/metastatic GC. To date, the prevalence of HER2 overexpression in the Korean population is unknown. The present study aimed to assess the incidence of HER2 positivity among GC and gastroesophageal (GE) junction cancer samples and the relationship between HER2 overexpression and clinicopathological characteristics in Korean patients...
March 2017: Journal of Gastric Cancer
https://www.readbyqxmd.com/read/28306358/the-genetics-of-gastroesophageal-adenocarcinoma-and-the-use-of-circulating-cell-free-dna-for-disease-detection-and-monitoring
#18
REVIEW
Mark R Openshaw, Catherine J Richards, David S Guttery, Jacqueline A Shaw, Anne L Thomas
Gastroesophageal adenocarcinoma (GOA) is a frequently occurring cancer worldwide with a poor clinical outcome. Adenocarcinomas of the esophagus and gastroesophageal junction have shown a recent increase in frequency, therefore there is need to increase our understanding of GOA in order to improve our ability to detect, monitor and treat the disease. Areas covered: The authors discuss the current classification of GOA in the context of recent changes in incidence. The authors also discuss developments in the understanding of disease biology and recent discoveries from whole genome and whole exome sequencing, and studies in immunotherapy...
May 2017: Expert Review of Molecular Diagnostics
https://www.readbyqxmd.com/read/28299508/prognostic-role-of-primary-tumor-location-in-non-metastatic-gastric-cancer-a-systematic-review-and-meta-analysis-of-50-studies
#19
REVIEW
Fausto Petrelli, Michele Ghidini, Sandro Barni, Francesca Steccanella, Giovanni Sgroi, Rodolfo Passalacqua, Gianluca Tomasello
INTRODUCTION: The incidence of gastric cancer (GC) arising in the upper third of the stomach, including the cardia or gastroesophageal junction (GEJ), has increased in the last decades due to established etiological risk factors such as diet, obesity, and gastroesophageal reflux. We conducted a systematic review and meta-analysis to determine the prognostic role of site of origin in patients with proximal versus distal GC. MATERIAL AND METHODS: We conducted a search of the PubMed, Cochrane Library, SCOPUS, Web of Science, EMBASE, Google Scholar, LILACS, and CINAHL databases from inception to September 2016...
March 15, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28279470/novel-targeted-therapies-for-esophagogastric-cancer
#20
REVIEW
Steven B Maron, Daniel V T Catenacci
Gastroesophageal cancer (GEC) remains a major cause of cancer-related mortality worldwide. Although the incidence of distal gastric adenocarcinoma (GC) is declining in the United States, proximal esophagogastric junction adenocarcinoma (EGJ) is increasing in incidence. GEC, including GC and EGJ, is treated uniformly in the metastatic setting. Overall survival in the metastatic setting remains poor. Molecular characterization of GEC has identified mutations and copy number variations, along with other oncogenes, biomarkers, and immuno-oncologic checkpoints that may serve as actionable therapeutic targets...
April 2017: Surgical Oncology Clinics of North America
keyword
keyword
110187
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"